Virbac: Customer stockpiling in North America has driven growth and favored a forecast revision

Virbac S.A. (i.) is a global pharmaceutical company that focuses exclusively on animal health. On October 17, the stock is expected to break out above a resistance line and the 20-day moving average. The trigger is a report for the third quarter presented after trading hours on October 16, along with an upward revision of the revenue forecast for the current year. The consolidated revenue of Virbac in the third quarter of 2025 amounted to EUR 364.1 million. This represents a very strong growth of +12.5% at constant exchange rates and consolidation...